BioLineRx (BLRX) Q4 2024 earnings summary

Executive summary

• Entered an exclusive license agreement with Ayrmid Ltd. (parent of Gamida Cell) for motixafortide (APHEXDA), excluding solid tumors and Asia, with $10M upfront, $87M in milestones, and 18–23% royalties on net sales.

• Shifted strategy to focus on lean drug development in oncology and rare diseases, shutting down U.S. commercial operations and reducing annual cash burn by over 70% effective January 2025.

• Completed financings raising $19M, including a $9M equity investment from Highbridge Capital, enabling significant debt repayment and restructuring with BlackRock.

• Transitioned U.S. commercial operations to Gamida Cell, extending cash runway into the second half of 2026.

• Refocused on drug development, especially in oncology and rare diseases, with plans to in-license one asset in 2025 and another in 2026.

Financial highlights

• 2024 revenue was $28.9M, up 502% year-over-year, including $6M in APHEXDA product sales and license payments.

• Q3 2024 revenue was $4.9M, including $3.2M from Gloria Biosciences license and $1.7M from APHEXDA sales.

• Cost of revenues rose to $9.3M in 2024, mainly due to amortization, royalties, and cost of goods sold.

• R&D expenses decreased 26% to $9.2M, reflecting lower motixafortide NDA costs and project terminations.

• Net loss narrowed to $9.2M from $60.6M in 2023, aided by $18.4M in non-operating income.

• Cash, equivalents, and short-term deposits were $19.6M at year-end 2024 ($29M pro forma post-January 2025 financing), expected to fund operations into 2026.

Outlook and guidance

• Cash runway extends into the second half of 2026, with a leaner cost structure and focus on clinical development in Israel.

• Plans to add three new clinical trial sites for the CheMo4METPANC phase 2b PDAC trial over the next two quarters, with interim data expected in 2026.

• Anticipates in-licensing one new asset in 2025 and another in 2026, focusing on early-stage oncology and rare disease candidates.

• Expects first revenues from China region in 2025 via Gloria Biosciences partnership.